Yale Pathology Tissue Services (YPTS) Shared Resource, sited in the Departs of Pathology is a longstanding shared resource providing broad tissue services to the Cancer Center and beyond. The Mission of YPTS is to provide the maximum amount and quality of human tissue for research at Yale University without impacting diagnostic quality, accuracy and safety in anatomic pathology. The service is structured into a modular architecture that integrates tissue procurement &distribution (TPD), developmental histology (DH), and clinical trials tissue services (GTTS). The TPD Module has nearly 50 standard operating procedures (SOPs) for collection of specific fresh tissue resources. About V4 of these protocols serve 12 YCC members representing about 30% of usage. The DH Module provides a range of histology services from standard tissue processing to quantitative analysis, whole slide imaging tissue microarray construction and analysis and laser capture microdissection. This facility has supported 71 YGC member users from all research programs, which represents about 29% of overall use. The GTTS module is a new addition to the resource since starting in 2010. Its function is to serve requests for tissue from cooperative group or other clinical trials that request a block or a portion of a block from the original diagnostic sample. The division reviews the original material and then ships cores of tissue blocks or recut slides to the requesting institutions. Their services are used by 6 YCC members representing about 26% of their usage. The facility is operated lead by Dr. David Rimm, assisted by Dr. Alex Vortmeyer. Each division has a technical director and there are 12 other physicians or technicians on the staff. Future plans include a move to a new larger laboratory and addition of new services included services in a CLIA certified lab and quantitative immunofluorescence services.

Public Health Relevance

Biospecimen access is a critical component of cancer research. The mission of this core is to maximize the access to biospecimens for all Yale Cancer Center users. The core both collects and processes tissue to optimize data that can be obtained from each specimen. Biospecimen collection and analysis contributes directly to the translational goals of users from nearly every program and project associated with cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-35
Application #
8755637
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
35
Fiscal Year
2014
Total Cost
$55,819
Indirect Cost
$22,294
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40
Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631
Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025
Wang, Shi-Yi; Long, Jessica B; Killelea, Brigid K et al. (2018) Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat 172:453-461
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331

Showing the most recent 10 out of 675 publications